GSK has continued its drive to bulk up its pipeline, taking global rights to a T-cell engager (TCE) for multiple myeloma, ...

RNA-targeted small molecules are rapidly emerging as one of the most exciting areas in drug discovery, with growing clinical validation demonstrating the potential to address historically undruggable ...

The planned IPO comes after Electra raised $183 million in a Series C that completed last October, as it started dosing ...

The organisation should not automatically double simply because revenue does. These are directional ranges, not rules, but they expose an important principle: headcount growth should normally lag ...

Khougazian – who is currently at investment group Flagship Pioneering – will take over as CEO of Chiesi on 15th October, ...

BioNTech and partner OncoC4's anti-CTLA-4 immunotherapy gotistobart almost doubled survival in a trial involving patients with a hard-to-treat form of lung cancer, ahead of a pivotal readout due next ...

The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

The offer is legally conditioned upon the private equity company's Respighi BidCo vehicle securing at least a two-thirds ...

GSK reported good clinical trial results with two of its lung cancer therapies – Jideytro and risvutatug rezetecan (ris-rez) ...

Etcamah is already approved in the US, Europe, and other markets for use in combination with a CDK4/6 inhibitor as a ...

Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...